DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Azilect (Rasagiline Mesylate) - Summary

 
 



AZILECT SUMMARY

AZILECT® (rasagiline tablets), 0.5 and 1 mg

AZILECT® Tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinson’s disease.

AZILECT (rasagiline tablets) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease as initial monotherapy and as adjunct therapy to levodopa.

The effectiveness of AZILECT was demonstrated in patients with early Parkinson’s disease who were receiving AZILECT as monotherapy and who were not receiving any concomitant dopaminergic therapy.  The effectiveness of AZILECT as adjunct therapy was demonstrated in patients with Parkinson’s disease who were treated with levodopa.


See all Azilect indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Azilect (Rasagiline)

Parkinson's Disease
Source: MedicineNet amantadine Specialty [2013.12.04]
Title: Parkinson's Disease
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 12/4/2013 12:00:00 AM

Parkinson's Disease Quiz: Test Your Medical IQ
Source: MedicineNet levodopa-carbidopa Specialty [2011.08.31]
Title: Parkinson's Disease Quiz: Test Your Medical IQ
Category: MedicineNet Quiz
Created: 8/23/2011 12:53:00 PM
Last Editorial Review: 8/31/2011 2:27:29 PM

Ease of Quitting Smoking May Be Early Sign of Parkinson's
Source: Medscape NeurologyHeadlines [2014.09.26]
People who reported they had a very easy time when they decided to stop smoking cigarettes were significantly more likely to develop Parkinson's disease than people who struggled to quit.
Medscape Medical News

Discovery of navigation system used by cancer, nerve cells
Source: Muscular Dystrophy / ALS News From Medical News Today [2014.08.27]
Duke University researchers have found a "roving detection system" on the surface of cells that may point to new ways of treating diseases like cancer, Parkinson's disease and amyotrophic lateral...

Human neurodegenerative diseases may be impacted by discovery of a new cellular garbage control pathway
Source: Huntingtons Disease News From Medical News Today [2014.07.22]
Several human neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and Huntington's disease but also ageing, are linked to an accumulation of abnormal and aggregated...

more news >>

Published Studies Related to Azilect (Rasagiline)

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. [2011.05]
BACKGROUND: The ADAGIO study investigated whether rasagiline has disease-modifying effects in Parkinson's disease. Rasagiline 1 mg per day, but not 2 mg per day, was shown to be efficacious in the primary analysis. Here, we report additional secondary and post-hoc analyses of the ADAGIO study... INTERPRETATION: These findings show that rasagiline delayed the need for symptomatic antiparkinsonian drugs and emphasise the contribution of the UPDRS ADL in the response of the rasagiline 1 mg per day early-start versus delayed-start group. The rate of UPDRS deterioration was less than was anticipated from previous studies and correlated with baseline severity. Understanding of the pattern of UPDRS deterioration is essential to assess disease modification. FUNDING: Teva Pharmaceutical Industries and H Lundbeck A/S. Copyright (c) 2011 Elsevier Ltd. All rights reserved.

Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. [2010.12]
Rasagiline is a selective, monoamine oxidase (MAO)-B inhibitor indicated for treatment of Parkinson's disease. This double-blind, placebo-controlled study determined the tyramine sensitivity factor (TSF) and degree of MAO-A inhibition (ie, reduction in plasma dihydroxyphenylglycol) in healthy volunteers who received phenelzine (15 mg, 3 times daily; positive control), selegiline (5 mg, twice daily), or rasagiline (1-6 mg, once daily) for 14 days or rasagiline 2 mg/d for 30 days...

Long-term efficacy of rasagiline in early Parkinson's disease. [2010.06]
This study was designed to follow the long-term efficacy, safety, and tolerability of rasagiline for Parkinson's disease (PD) with data collected from all patients who had ever taken rasagiline during the 12-month TEMPO monotherapy trial (N = 398) and subsequent open-label extension... Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial.

The role of rasagiline in the treatment of Parkinson's disease. [2010.05.25]
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic therapies while neuroprotective strategies have remained elusive.The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established.

Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. [2010]
Rasagiline is a selective, monoamine oxidase (MAO)-B inhibitor indicated for treatment of Parkinson's disease. This double-blind, placebo-controlled study determined the tyramine sensitivity factor (TSF) and degree of MAO-A inhibition (ie, reduction in plasma dihydroxyphenylglycol) in healthy volunteers who received phenelzine (15 mg, 3 times daily; positive control), selegiline (5 mg, twice daily), or rasagiline (1-6 mg, once daily) for 14 days or rasagiline 2 mg/d for 30 days...

more studies >>

Clinical Trials Related to Azilect (Rasagiline)

A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease [Completed]
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD:

- Group 1 Patients using Azilect and no other therapy.

- Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or

Requip.

Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease [Recruiting]

Study of Rasagiline in Levodopa-treated PD Patients With Motor Fluctuations [Recruiting]
To evaluate the efficacy of a fixed dose of rasagiline (1 mg/day) vs placebo as assessed by the change from baseline in mean total daily OFF time during 18 weeks of treatment in levodopa-treated Parkinson's Disease (PD) patients with motor fluctuations.

Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn [Recruiting]
The primary endpoint for this study is the clinical response after 12 weeks of treatment, defined as a change in total score from baseline depressive symptoms as measured by the Beck Depression Inventory-Amended (BDI-IA) total score.

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients [Recruiting]
A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease even in the earliest stages of the disease. There have been no treatments that have been proven to improve sense of smell in patients with Parkinson's Disease.

Rasagiline (brand name: Azilect) was approved by the U. S. Food and Drug Administration (FDA) on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated with the disease. The purpose of this study is to see if there is change in sense of smell after starting Rasagiline.

more trials >>

Reports of Suspected Azilect (Rasagiline) Side Effects

Dizziness (15)Drug Interaction (14)Headache (13)Arthralgia (11)Dyskinesia (9)Fall (9)Hallucination (9)Diarrhoea (9)Insomnia (9)Confusional State (8)more >>


Page last updated: 2014-09-26

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014